摘要
According to the latest global cancer statistics,colorectal cancer(CRC)is the most common malignancy of the digestive system and the second most lethal among all cancer types(1).In China,CRC is the second most prevalent cancer,following only after lung cancer(2).The first version of the Chinese Society of Clinical Oncology(CSCO)guideline was launched in 2017 and has been updated annually based on the latest findings of clinical research,drug accessibility and expert consensus(3-8).Here,we present the main updates of the 2024 version compared to the 2023 version.
基金
supported by the Provincial Key R&D Program of Zhejiang Province(No.2021C03125)
National Natural Science Foundation of China(No.82373415 and No.82302489)
Beijing Xisike Clinical Oncology Research Foundation(No.Y-tongshu2021/ms-0003).
